Mechanisms of Benefits of SGLT2 Inhibitors in Patients With HFpEF
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
European Heart Journal
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction
Eur Heart J 2023 Sep 07;[EPub Ahead of Print], AK Pandey, DL Bhatt, A Pandey, N Marx, F Cosentino, A Pandey, S VermaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.